Analysis of macrophages and neutrophils infiltrating murine mammary carcinoma sites within hours of tumor delivery

Zhang, Chenyu; Adusei, Matthew; Baranovic, Alison; DeBenedetto, Matthew; Lauricella, Amanda; Martin, Silvia Chilel; Newsom-Stewart, Catherine; Schwartz, Jennifer; Kurt, Robert A.

doi:10.1016/j.cellimm.2019.103929

Cited by 4 publications

(12 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Luo et al [33], using a 4T1 matrigel model, found macrophages (CD68 + ) by IHC at day 6 tumor sites, but the cells were not quantified and no further analysis of the cells was conducted. Our lab [11] used a gelfoam model to study early 4T1 tumor sites (days 1 and 3 post-tumor delivery) and found approximately 40% of the infiltrating cells were macrophages (F4/80 + ) and 20% were neutrophils (Ly6G + ). Further analysis of these cells revealed production of TNF-α and TGF-β, the cells were phagocytic, and by day 3, the macrophages exhibited a higher dependence on oxidative phosphorylation and the neutrophils showed a decrease in production of reactive oxygen species (ROS) relative to day 1 cells.…”

Section: Transplantable/orthotopic Mouse Modelsmentioning

confidence: 99%

“…The only effector function assessed was phagocytic activity of the macrophages which were phagocytic at day 7, and they did not lose this activity until day 21. Our lab [11] used the gelfoam model to study early EMT6 tumor sites (days 1 and 3) and found approximately 40% of the infiltrating cells were macrophages (F4/80 + ) and 20% were neutrophils (Ly6G + ). Further analysis of the macrophages revealed a significant increase in TNF-α and TGF-β production between day 1 and day 3 post-tumor delivery, and by day 3, the macrophages exhibited a greater dependence on oxidative phosphorylation and the macrophages and neutrophils showed a decrease in ROS production relative to day 1 cells.…”

Section: Transplantable/orthotopic Mouse Modelsmentioning

confidence: 99%

“…With the 168 breast cancer model, approximately 20-40% of the cells at early tumor sites (days 1-3) are macrophages (F4/80 + ) and neutrophils (Ly6G + ) [11]. In addition, these cells produce TNF-α and TGF-β and are phagocytic.…”

Section: Transplantable/orthotopic Mouse Modelsmentioning

confidence: 99%

“…For example, Carron et al [10] used a p53−/− mammary carcinoma model and found that there was an increase in pro-and anti-tumor macrophages before the tumor was even palpable, and that the macrophages present at this early stage of disease contributed to tumor progression. Zhang et al [11] found macrophages with some M1 and M2 characteristics at early sites of three different murine mammary carcinomas. In patients, macrophages are also present at early sites of breast cancer, yet we still do not know what these cells are doing at this site even though McKee et al [12] reported almost 20 years ago that the presence of macrophages was among the characteristics for high-grade ductal carcinoma in situ (DCIS).…”

Section: Introductionmentioning

confidence: 97%

See 3 more Smart Citations

Indicators of a pro-tumor immune response are evident at early stages of breast cancer

Zhang

Kurt

2020

Clin Transl Oncol

View full text Add to dashboard Cite

With advances in checkpoint inhibitor and CAR T-cell therapies, among other advances in immunotherapy, this is an exciting time to be a tumor immunologist. We are witnessing the transition of decades of work at the bench leading to substantial success in the clinic. While work continues developing new and improving existing immunotherapies, there remains a great deal of basic tumor immunology still to learn, information that can only lead to greater success in the clinic. One area in need of more attention is understanding the immune response at early stages of breast cancer. While there is no question that early diagnosis and treatment save lives, a greater understanding about the immune response during early stages of breast cancer may reveal information that could assist in monitoring individuals at risk of breast cancer, and could have implications for patients diagnosed at early stages of disease, and may provide important information about the origins of an immune-suppressive environment. Here, we review studies that have looked at the very early immune response to breast cancer focusing on patients with DCIS, before invasion in spontaneous transgenic murine mammary carcinoma models, and before transplantable or orthotopic murine mammary carcinoma models become palpable. The findings revealed that indicators of a pro-tumor immune response are already present at early stages of disease.

show abstract

Section: Transplantable/orthotopic Mouse Modelsmentioning

confidence: 99%

Section: Transplantable/orthotopic Mouse Modelsmentioning

confidence: 99%

Section: Transplantable/orthotopic Mouse Modelsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Indicators of a pro-tumor immune response are evident at early stages of breast cancer

Zhang

Kurt

2020

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

“…CXCL10 has two opposite effects in tumours and can promote and inhibit cancer progression(6). Many researchers have reported that CXCL10 is associated with tumour-in ltrating neutrophils (TINs) and promotes tumour progression in pancreatic, cholangiocarcinoma, breast, gastric, colorectal and bladder cancers (7)(8)(9)(10)(11)(12). Most studies have shown that CXCL10 is related to malignant phenotypes such as tumour proliferation and metastasis, suggesting that it is related to poor prognosis in cancer patients.…”

Section: Introductionmentioning

confidence: 99%

CXCL10 Expression in Tumor Tissues and is An Independent Prognostic Indicator of Pancreatic Cancer

Hu¹,

Xu²,

Zhong³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Pancreatic cancer is a malignant disease with difficult diagnosis and high mortality. The most common type is pancreatic duct adenocarcinoma (PDAC). CXCL10 is of great significance in the treatment of immune diseases and cancer. Here, we evaluated the expression of CXCL10 in pancreatic cancer and its clinical significance. Results: The results of the TCGA database showed that the expression of CXCL10 in pancreatic cancer tissues was higher than that in matched adjacent tissues (P <0.05). Patients with high expression of CXCL10 had a poor prognosis compared with those with low expression of CXCL10 (P=0.0051).We found that CXCL10 was positively and strongly correlated with tumour-infiltrating neutrophils and macrophages in PDAC (P<0.0001). We also performed CXCL10 immunohistochemical staining in a tissue microarray (TMA), which included tumour samples collected from 119 PDAC patients (each sample was matched with an adjacent tissue sample). The expression level of CXCL10 in PDAC tissues was prominently higher than that in the matched adjacent tissues (P = 0.0001). Analysis of clinicopathological factors suggested that the high expression of CXCL10 was correlated with the patient's T stage (P = 0.020). In addition, higher CXCL10 expression was significantly associated with worse overall survival of PDAC patients (P = 0.012). The results of COS multivariate analysis suggested that age (P=0.005), histological grade (P=0.001), TNM stage (P=0.017) and CXCL10 expression (P=0.024) were independent prognostic factors for pancreatic cancer. Conclusion: Our data indicate that CXCL10 is highly expressed in PDAC and may be used as an independent clinical prognostic indicator for PDAC.

show abstract

The Impact of Tumor-Associated Macrophages Found at Mammary Carcinoma Sites is Dependent Upon the Tumor Type

Chang,

Ellmaker,

Esposito

et al. 2023

Immunological Investigations

View full text Add to dashboard Cite

Analysis of macrophages and neutrophils infiltrating murine mammary carcinoma sites within hours of tumor delivery

Cited by 4 publications

References 62 publications

Indicators of a pro-tumor immune response are evident at early stages of breast cancer

Indicators of a pro-tumor immune response are evident at early stages of breast cancer

CXCL10 Expression in Tumor Tissues and is An Independent Prognostic Indicator of Pancreatic Cancer

The Impact of Tumor-Associated Macrophages Found at Mammary Carcinoma Sites is Dependent Upon the Tumor Type

Contact Info

Product

Resources

About